This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
|Videos|November 4, 2021
Dr. Tina Q. Tan discusses the COVID-19 vaccine in kids 5-11 years
Author(s)Miranda Hester
Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the approval of the COVID-19 vaccine for children aged 5 to 11 years and conversations with parents.
Advertisement
The authorization of the Pfizer/BioNTech COVID-19 vaccine in children aged 5 to 11 years has been met with positive reactions from pediatricians and many parents. As the rollout to the age group starts, allaying safety fears and knowing who to turn to for the vaccine are key. The editor-in-chief of Contemporary Pediatrics, Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, sat down with the editorial team to answer some common questions.
Advertisement
Related to this article
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.
The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.
AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.
Lori Handy, MD, says vaccine conversations with hesitant families should prioritize trust, follow-up, and the benefits for the individual child.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Suicide-related emergency department visits in US children rose 74% from 2016 to 2022
2
Fenfluramine shows sustained seizure reduction, functional improvement in Lennox-Gastaut syndrome
3
Lavengratinib shows early growth signal in phase 2 achondroplasia study
4
Satralizumab for MOGAD gains FDA priority review after phase 3 relapse reduction
5